The market of wound management devices is expected to grow substantially during the forecasted period, registering a CAGR of 4.3% from 2019 to 2026 due to increasing prevalence of chronic wounds which requires high cost, proper management and longer time to heal. It has been predicted that healing of one diabetic ulcer costs approximately US$ 50,000 and chronic wounds as a whole cost over US$25 billion per year, with the number of affected individuals growing rapidly each year.
GET SAMPLE COPY @ https://www.reportocean.com/industry-verticals/sample-request?report_id=AMR927
The global wound management devices market size was valued at $13,396.8 million in 2018 and is anticipated to reach $18,818.4 million by 2026. The market of wound management devices is segmented on the basis of:.
By Product type
- Marketed
- Emerging
- By Products
- Therapy devices
- Wound closure devices
- Others
By Applications
- Diabetic foot ulcers
- Burns
- Pressure ulcers
- Surgical wounds
- Others
By End Users
- Hospitals
- Clinics
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- Spain
- Italy
- UK
- Rest of Europe
- Asia-Pacific
- Japan
- India
- China
- Australia
- South Korea
- Rest of APAC
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
The wound management market is majorly driven by rise in incidences of chronic wounds, increasing cases of diabetes, lifestyle leading to diabetes and obesity and the technological advancements in wound care unit. However, the high treatment cost is expected to be the major restrain in the market growth globally. Moreover, lack of proper reimbursement also restricts the market growth.
The wound closure devices are highly demanded in the market. Earlier, these devices can only heal the tissue mechanically but not in biological manner. Recently, the bioactive wound closure devices bring about the implausible economic benefits and raise the demand of these devices. On the other hand, therapy devices are in demand due to the large number of approved products in the market.
Among end users, the hospital’s out patient segment with a cost of approximately ~US$ 30 billion in recent years lead the global market. This number is estimated to rise in the forecasted period, 2017–2026.
In the world’s largest wound management markets, United States and Europe, there is a high demand for wound care products. In the United States, ~6.5 million population have chronic wounds, and appropriate therapy and care costs around US$ 25 billion annually. The worldwide annual cost for wound care was an average of $2.8 billion in 2014. It is expected to rise up to 9.4% of the US population have diabetes and foot ulcers are quite common in diabetic population, the wound management for foot ulcers costs $9–$13 annually. Across the globe, players from the US, China, and Japan are hold the leading positions in the wound management market as these countries hold maximum number of patents, followed by Germany and the United Kingdom.
Developing a potential product for commercialization is an approach to minimize the uncertainty and maximize the growth. The wound management has certain concepts, which include homeostasis, wound cleaning, analgesia, wound closure and dressing. Several key players are involved in the commercialization and development of devices required for wound management. These include Rochal Industries LCC., Kerecis Limited, Applied Tissue Technologies, MolecuLight, Convatec Group Plc, PRP Concepts, LLC. and others.
Marketed Devices
Bioshield Silicone Film developed by Rochal Industries LCC. is a silicone, penetrable spray-on bandage used for incisions as well as excisions. The polymer used resembles the human skin in terms of transport and mechanical properties, due to which it potentially protects the surgical sites and wounds of the body. This medical device is approved by the FDA in October, 2019.
MariGen is an Omega 3 rich extracellular matrix derived from fish skin. It is used as a scaffold on the wound on which body’s own cells grow. Product is then ultimately converted to functional tissue. This device from Kerecis Limited has been approved by the FDA in July, 2019.
Negative pressure wound therapy (NPWT) provides multiple unique mechanisms to aid wound healing including macrodeformation, microdeformation, removal of excess tissue edema and perfusion. The United Stated has been using this device since 1990s but healthcare professional need some alteration in the device in order to increase its efficacy. The need to place some filler material in the wound area.
The Applied Tissue Technologies tried to incorporate a permanent impermeable membrane into the device which exempt the use of separate filler. This modified device has been approved by the Food and Drug Administration in January,2019.
A hand-held fluorescent imaging device called MolecuLight i:X can heal patients rapidly by detecting the harmful bacteria in wounds and allowing targeted treatment. MolecuLight received the FDA approval for i:X device in August, 2018. This non-invasive device emits a violet light to illuminate the bacteria.
ZipStitch from ZipLine Medical is a surgical quality wound closure used to close minor lacerations quickly without puncturing the skin. It received the FDA approval in August, 2017. It is a new first aid tool to close serious cuts. It consists of four zip-ties that are connected by two 4 cm super-adhesive bandages. The zips connect bandage in a locking mechanism to heal the wound.
Emerging Devices
Fibrin Bio-Matrix is in the phase II of interventional studies at PRP Concepts, LLC. Platelet rich plasma gel (PRP) can either be prepared through standard blood banking techniques or through care device. The use of this device is investigated in ulcers or wounds that can turn chronic like diabetic foot ulcer or pressure ulcer.
Sham (SBI-101) is designed to regulate inflammation and repair injured tissue using allogeneic human mesenchymal stromal cells to avoid renal replacement therapy in case of acute kidney injury. It was initiated in June, 2017 at Sentien Biotechnologies, Inc. and has reached phase II of clinical studies.
Healing of a chronic wound is lengthy and complex process, as wound healing is the replacement of damaged tissues by the newly developed tissues in the living organism. This process is depicted in three discrete phases, inflammatory, proliferative and maturation. In 2018, ∼8.2 million individuals had wounds with or without infections, out of which 18% are acute and 82% are chronic in nature. And cost for the treatment of acute and chronic wounds ranged from US$ 28.1 billion to US$ 96.8 billion.
Epidemiology Insights
The Global Wound Management Devices Research Report offer insights for epidemiology based on:
- Total Prevalent Population of Wound in 9MM
- Total Diagnosed Prevalent Population of Wound in 9MM
- Type-specific Diagnosed Prevalent Population of Wound in 9MM
- Age-specific Diagnosed Prevalent Population of Wound in 9MM
Acute wounds can either be traumatic or surgical. Elderly population is more likely to undergo chronic wounds due to degradation of the elastic tissue and collagen fibres in the outer layer of skin. In the United States, more than 3% of population with chronic wounds falls under the category of more than 65 years of age. The elderly patient population with the chronic wound was 40 million in 2010 and is expected to increase up to 55 million this year in the US alone.
Apart from age, rising prevalence of diabetes and obesity issues are some major factors that support the dramatic increase of chronic wounds. Stiffening of the arteries, narrowing of blood vessels and other changes within the body of diabetic person, increases the risk of wounds. Similarly, the insufficient oxygen levels in obese individuals makes the leukocytes incapable to heal wounds. This also highly impact the wound healing process.
Diabetes and obesity can result in increasing number of ulcers such as leg or foot ulcers, which necessitate the lifetime wound treatment, as well as high medical costs. However, this rise in demand leads to the development of advanced wound healing therapies including oxygen-associated therapies and Negative pressure wound therapy (NPWT). Oxygen-associated therapies are helpful in diabetic-foot ulcers. The occurrence of pressure ulcer increases with age and is prompted by lack of skin perfusion and moisture.
Impact of coronavirus pandemic on wound management market
The coronavirus pandemic will show a marginal impact on the advance wound management market. The diabetics and obese being more prone to virus would generate greater risk of chronic wounds which in turn elevates the wound management devices market. Moreover, patients with multiple comorbidities may have higher risk of viral infection which also increases the demand of wound management. However, amidst this pandemic situation typical wound care paradigms have been affected. Disruption of wound care centers and a shift of concern to other health care environments, with greater emphasis on care within home will limit the scope of growth of the market.
Have Any Query? Ask Our Experts: https://www.reportocean.com/industry-verticals/sample-request?report_id=AMR927
About Report Ocean:
We are the best market research reports provider in the industry. Report Ocean believe in providing the quality reports to clients to meet the top line and bottom line goals which will boost your market share in today’s competitive environment. Report Ocean is “one-stop solution” for individuals, organizations, and industries that are looking for innovative market research reports.
Get in Touch with Us:
Report Ocean
Name: Nishi Sharma
Email: sales@reportocean.com
Address: 500 N Michigan Ave, Suite 600, Chicago, IIIinois 60611 – UNITED STATES
Tel: +1 888 212 3539 (US – TOLL FREE)
Website: https://www.reportocean.com/
